, and is also involved in cancer development [13] [14] [15] [16] . PSCs produce LIF [17] [18] [19] , but its physiological significance in PDAC tumorigenesis is unclear. We first assessed LIF activity in vitro and found a widespread response in PCCs but not in activated PSCs and normal fibroblasts, and among three reported downstream pathways 12 , STAT3 was robustly activated, whereas ERK and AKT pathways were not (Extended Data Fig. 2a, b) . LIF signalling blockade by either LIFR knockdown in PCCs or LIF ligand immunodepletion from PSC-conditioned medium effectively abolished STAT3 activation, providing further supporting evidence for LIF as the predominant paracrine factor for STAT3 activation in PCCs (Fig. 1f, g and Extended Data Fig. 2c, d) . Moreover, the variable response of PCCs to LIF was dependent on the level of LIFR, and paracrine interaction was the predominant mode of LIF action (Extended Fig. 2e, f) . We then validated LIF dysregulation in vivo, and observed that LIF protein level was undetectable in normal pancreas but markedly increased in PDAC tissues (Fig. 1h) . Furthermore, in both mouse and human PDAC tissues LIF mRNA was abundant in activated PSCs-especially in those adjacent to cancer cell nests-but sporadic in a small fraction of cancer cells and barely detectable in CD45
+ immune cells or normal pancreatic tissues, reaffirming activated PSCs as the major LIFproducing cells (Fig. 1i , j and Extended Data Fig. 2g ). Correspondingly,
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STAT3 was also markedly activated in PDAC tissues (Extended Data Fig. 2h-j) . Together, these findings indicate that LIF is involved in PDAC pathogenesis.
Although STAT3 activation has been documented to be essential for PDAC tumorigenesis, the underlying mechanisms and the cellular source(s) of STAT3-activating cytokines have been debated [8] [9] [10] 20 . On the basis of our finding that PSC-produced LIF is a key STAT3 activator, we evaluated its physiological significance in PDAC. As PCCs are the major Lifr-expressing cells and therefore presumably the main target of LIF action, we generated CL mice, indicating that LIFR signalling in PCCs itself has an important role in PDAC development. Survival was further prolonged by gemcitabine (Gem) administration, implying an additional role for LIFR signalling in increasing chemoresistance (Fig. 2a) . Correspondingly, the relative abundance of PCCs in tumours was decreased in Lifr-deficient mice and by Gem treatment (Fig. 2b) . Notably, although almost all pancreatic epithelial cells were transformed into cancer cells in Lifr ;Pdx1-Cre) mice to directly evaluate the effect of LIF on tumour initiation, comparable PanIN grades were induced (Extended Data Fig. 3h, i) . d, e, Immunoprecipitation followed by mass spectrometry (IP-MS) assay on PANC1 cells expressing 3×Flag-STAT3 to identify conditionedmedium stimulation-dependent STAT3-associated proteins. n = 3 biological replicates. f, g, Immunoblot analyses of pSTAT3 in KP4 cells with LIF blockade by LIFR knockdown or LIF monoclonal antibody. Conditioned medium was collected from hPSC. shNC, control shRNA; shLIFR#1 and shLIFR#2, LIFR shRNAs; mAb, monoclonal antibody. h, LIF levels in mouse pancreatic normal and tumour tissues by ELISA. n = 7 (normal tissue); n = 8 (PDAC). i, j, RNAscope assays to examine cellular sources of LIF mRNA expression in mouse (i) and human (j) pancreatic tissues. Sections were co-stained for KRT19 mRNA to mark cancer cells. NT, mouse normal pancreatic tissues or non-tumour parts resected from the human tumour trunks; PDAC, tumour tissues collected from KP f/f CL mice or patients with PDAC. Scale bars, main, 200 µm; inset, 50 µm. Representative images from at least three biological replicates per experiment are presented (f, g, i, j). P a n I N 1 a / b P a n I N 2 P a n I N 3 P D A C 
Moreover, no apparent differences were observed in the formation and resolution of acinar-ductal metaplasia between caerulein-treated Lifr WT ;Pdx1-Cre and Lifr f/f ;Pdx1-Cre mice (Extended Data Fig. 3j ). In summary, these genetic studies demonstrate that LIF mainly acts on PCCs to facilitate tumour progression, but not initiation.
Having established LIF as a promising therapeutic target, we evaluated it preclinically using the KP f/f CL mouse model with a LIFneutralizing monoclonal antibody 23 (LIF blockade) (Extended Data Fig. 5a -e). Similar to genetic Lifr depletion, the overall survival of KP f/f CL mice was increased by LIF blockade, and further prolonged by treatment with a combination of LIF blockade and Gem (hereafter, 'combo'), with reduced tumour burden, even in comparison with Gem treatment with control IgG (hereafter, 'chemo'), further corroborating the prominent roles of LIF in PDAC progression and chemoresistance (Fig. 3a, b) . The combo treatment significantly reduced the abundance of PCCs, but not that of PSCs, and evaluation of PCCs showed increased proliferation accompanied by enhanced apoptosis (Extended Data Fig. 5f-j ). An increase in proliferation of PCCs could enhance their susceptibility to Gem treatment, thus promoting apoptosis and consequently alleviating chemoresistance. Blinded histopathological examinations by independent pathologists consistently found that combo-treated KP f/f CL tumours appeared more differentiated ( Fig. 3c and Extended Data Fig. 6a ), suggesting that LIF blockade promotes cancer cell differentiation and leads to a less aggressive and more drugsusceptible phenotype. To understand this effect, we assessed the relative abundance of PCCs by differentiation status and found that the populations of tumour-initiating cells expressing the markers ALDH, CD133, CD24 and CD44, or cMet [24] [25] [26] [27] [28] , were all markedly reduced by the combo treatment, as functionally validated by both in vitro sphere formation and in vivo flank transplantation assays (Fig. 3d-f and Extended Data Fig. 6b-d) , and consistently observed in the Lifr-deficient genetic mouse model (Extended Data Fig. 4a-c) . Furthermore, in short-term in vivo combo-treated PCCs, besides tumour-initiating cell-marker genes and those involved in negative regulation of stem cell differentiation, the expression of genes critical for epithelial-mesenchymal transition (EMT) was also downregulated-as further confirmed by the reduced abundance of ZEB1 + mesenchymal PCCs ( Fig. 3g and Extended Data Figs. 6e, 7b, c). The expression of many cascade components and downstream target genes in the Hippo, Wnt and STAT3-signalling pathways was significantly suppressed, accompanied by changes in gene expression leading to a heightened Gem response ( Fig. 3h and Extended Data Fig. 7d, e) . EMT induction and the emergence of tumour-initiating cells are intertwined biological processes that facilitate chemoresistance in cancers and are regulated by several developmental signalling cascades, including STAT3, Hippo and Wnt
29
. Moreover, the differential geneexpression signatures were also recapitulated in the Lifr-deficient genetic model (Extended Data Figs. 4d-i, 7f, g ).
We observed dual roles of LIF, affecting both tumour progression and Gem response. As delayed progression could impact Gem response, we assessed the direct effect of LIF on sensitivity to Gem. When freshly isolated primary PCCs were subjected to low-dosage Gem treatment, the sphere-forming capacity was markedly suppressed in Lifr-deficient PCCs, indicating that the intrinsic chemoresistance of tumourinitiating cells relied on LIFR signalling (Extended Data Fig. 6f) . In this setting, the combo treatment resulted in an even more marked therapeutic benefit with substantially prolonged survival, characterized by markedly reduced mesenchymal-transited PCCs and increased PCC differentiation and apoptosis (Fig. 4a-e and Extended Data Fig. 6g-i ). This evidence further emphasizes the importance of LIF in chemoresistance and reinforces its translational potential as a therapeutic target, given that PDAC is usually diagnosed late with strong intrinsic chemoresistance and the urgent need for therapeutics to alleviate chemoresistance after the first-line chemotherapy. 
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As LIF mediates tumour progression, and LIF-producing PSCs are activated very early and gradually increase in abundance during PDAC tumorigenesis, we tested for correlation between LIF and PDAC pathogenesis. LIF levels were already markedly elevated in the pancreas of KP f/f CL mice at three weeks of age, when mainly pancreatitis and early PanIN lesions with a few small solid tumour nodules were evident, and then steadily increased during tumour progression (Extended Data Figs. 3f, 8a). Notably, increased LIF production and STAT3 activation were readily detectable in caerulein-induced pancreatitis, in which PSCs are transiently activated but tumour development is not yet initiated, supporting LIF production by activated PSCs (Extended Data Figs. 2j, 8a-c). To examine its relevance to human PDAC, we quantified LIF levels in human pancreatic tissues, and observed a substantial elevation in all 77 PDAC cases compared with paired normal tissues, as well as an apparent trend of increase in chronic pancreatitis tissues ( Fig. 5a and Extended Data Fig. 8e ). Similar observations were recapitulated in an independent set of human pancreatic specimens by parallel reaction monitoring-based targeted mass spectrometry (PRM-MS) assays, obviating the potential limitations of enzyme-linked immunosorbency assays (ELISA) (Extended Data Fig. 9a-h ). Of note, among various pathological parameters, LIF levels correlated with PDAC differentiation status as well as overall survival, paralleling LIF mRNA levels revealed by The Cancer Genome Atlas (TCGA) RNA-seq data (Fig. 5b, c and Extended Data Fig. 8f, g ). These correlations, albeit indirect, demonstrate the physiological importance of LIF in human PDAC pathogenesis, and add to the evidence corroborating LIF regulation of cancer cell differentiation.
The correlation between LIF and tumour pathology in both mouse and human PDAC suggested LIF as a potential disease-monitoring marker. As clinical application requires sample acquisition to be easy and noninvasive, we evaluated the levels of LIF in blood samples by ultra-sensitive ELISA assays and readily observed their elevation in PDAC conditions ( Fig. 5d and Extended Data Fig. 8d ). Among a cohort of 14 patients with PDAC who were treated with preoperative chemotherapy, changes in circulating LIF levels in serial blood samples collected longitudinally during treatment correlated with therapeutic responses, and were an independent and better indicator than carbohydrate antigen 19-9 (CA19-9), the only FDA-approved PDAC biomarker in clinical use (Fig. 5e , f and Extended Data Fig. 8h ). LIF elevation in both blood and primary tissues was present in PDAC and absent in other common solid cancers (Extended Data Figs. 8i, 9f). Collectively, these findings highlight that LIF is a promising marker for monitoring PDAC status and/or therapeutic response.
Interleukin-6 (IL-6) has been implicated in PDAC, and like LIF, all interleukin family members bind to receptor complexes containing GP130 to activate similar signalling cascades, such as the STAT3 pathway. In our initial screens, IL-6 and IL-11 were also found to be produced by PSCs (Extended Data Fig. 10a-e) . Because the IL-11 level was below its effective concentration (data not shown), we focused on side-by-side comparison of IL-6 and LIF in PDAC. Although the concentration of IL-6 was significantly increased in mouse PDAC, it was very low in both human PDAC primary tissues and blood (Extended Data Fig. 10f-i) , and was below the detection threshold of PRM-MS in primary PDAC tissues (data not shown). Consistently, IL6 expression in human PDAC tissues was much lower and did not correlate with pathological parameters (Extended Data Fig. 10j-m, o) . Furthermore, in accordance with our findings that fewer PCC lines responded to IL-6, IL6R mRNA expression in human PDAC tissues was markedly lower than LIFR mRNA, precluding a direct action of IL-6 on PCCs (Extended Data Fig. 10n-p) . These findings underscore the importance of LIF over IL-6 in human PDAC. Moreover, contributions of other PSC-secreted cytokines are likely to be minimal, as there was no detectable increase in pSTAT3 when LIF and IL-6 activity in hPSCconditioned medium were neutralized (Extended Data Fig. 10q ).
In summary, using quantitative proteomics, we systemically investigated paracrine communication between PSCs and PCCs, and identified LIF as a critical stromal factor that acts on PCCs. Functional studies revealed the physiological significance of LIF in driving both tumour progression and chemoresistance (Extended Data Fig. 8j) , and highlighted its translational potential (details in Supplementary Discussion). This translational promise is reinforced and broadened by the marked correlation of tissue and circulating LIF with pathological parameters, and the specific elevation and high abundance of LIF in PDAC. As such, LIF represents an attractive therapeutic target and biomarker in PDAC and warrants further comprehensive evaluation for clinical application.
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Cell lines. The human pancreatic cancer cell lines AsPC1 (CRL-1682), BxPC3 (CRL-1687), CFPAC1 (CRL-1918), MIA PaCa2 (CRL-1420), PANC1 (CRL-1469) and BJ fibroblasts (CRL-2522) were acquired from ATCC, and KP4 (JCRB0182) was acquired from JCRB, and cultured per the supplier's instructions. HPDE6C7 was provided by the Tsao group (University of Toronto) and cultured as previously described 31 . The spontaneously immortalized human pancreatic stellate cell line hPSC, ONO and YAM1 were provided by the Evans group (Salk) as previously described 11 . Normal human fibroblast cells were a gift from the Gage group (Salk) No sexual dimorphism was noted in any mouse model, and therefore males and females were equally used for experimental purposes and both sexes are represented in all datasets. Mice were bred and maintained in the animal care facilities at the Salk Institute. Genotype of individual mice was determined by PCR using genomic DNA from tail biopsies with the Bioline MyTaq Extract-PCR Kit. Standard PCR per the manufacturer's protocol was performed, annealing at 58 or 60 °C for 35 cycles. Primer sequences are available upon request. All animal experiments were performed according to protocols approved by the Salk Institute Animal Care and Use Committee. Human specimens. All the human frozen tissues and serum or plasma specimens were in existence, and provided as de-identified samples. Serial plasma samples were collected with informed consent from the patients and provided to us for ELISA analysis with the approval by Salk Institutional Review Board (IRB) with protocol #17-0005. Human serum samples were provided by UCSD Moores Cancer Center BTTSR (supported by CCSG Grant P30CA23100), UNMC Rapid Autopsy Pancreatic Program (supported by P50CA127297, U01CA210240, P30CA36727 and 5R50CA211462), C.R. Becerra (supported by The Jeanne Shelby Fund for Cancer Research of Communities Foundation of Texas) and E. Borazanci. Lentiviral constructs and production. shRNA constructs were purchased from the RNAi Consortium or Addgene as follows: human shLIFR #1, TRCN0000430362 with target sequence ACTTCTGCAGATTCGATATTA, and #2, TRCN0000427511 with target sequence TGAAGTGTGTAACTAACAATT; and scramble shRNA (shNC), Addgene # 1864 with hairpin sequence as CCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGG. Lentivirus was produced in 293T cells transfected with shRNA constructs along with pRSV/REV, pMDLg/pRRE and pCMV-VSVG packaging constructs. Viral supernatants were collected 48 h after transfection, spun for 5 min at 3,000 r.p.m. and filtered. Target cells were infected by incubation in viral supernatants for 6 h, and selected with 2 mg/l puromycin 36 h after infection. Reverse transcription PCR and quantitative PCR. RNA was isolated using NucleoSpin RNA II kits (Clontech) and converted to cDNA using M-MLV Reverse Transcriptase (Invitrogen). Quantitative PCR (qPCR) was performed using ABI qPCR 7900HT (Thermo Fisher Scientific) by mixing cDNAs, Power SYBR Green PCR Master Mix (Invitrogen), and gene-specific primers. ACTB was used as internal control for normalization. Data were analysed using SDS2.4 software. Primer sequences are: hLIFR-qF: CGAGCCTATACAGATGGTGGA, hLIFR-qR: CCATTCTCGTTTCCGATA GC; hACTB-qF: TCCCTGGAGAAGAGCTACGA, hACTB-qR: TACAGGTCTTTGCGGATGTC. RNA-seq and bioinformatic analysis. Whole tumours from each mouse were individually resected, dissociated into single-cell suspension by enzyme digestion, and ~10 5 EpCAM + pancreatic cancer cells were isolated by FACS and directly lysed in RA1 lysis buffer for RNA extraction using NucleoSpin RNA II kits (Clontech) per the manufacturer's protocol. All sequencing libraries were then sequenced at single-end 50 base pair (bp) on an Illumina HiSeq 2500 by the Salk Institute Next Generation Sequencing (NGS) Core. Raw sequencing data were demultiplexed and converted into FASTQ files using CASAVA (v.1.8.2). Sequenced reads were quality tested using FASTQC 33 (v.0.11.2) with the default parameters. Alignment to the mm10 genome was performed using the STAR aligner 34 (v.2.4.0k). Mapping was carried out using default parameters (up to ten mismatches per read, and up to nine multi-mapping locations per read). Raw gene expression was quantified across all gene exons using the top-expressed isoform as proxy for gene expression, and differential gene expression analyses were carried out using the edgeR 35 package (v.3.6.8) using replicates to compute within-group dispersion. Differentially expressed genes were defined as having a false discovery rate (FDR) <0.05 and a log 2 fold change >0.8. Hierarchical clustering was performed using the R language (v.3.3.2) with Ward's hierarchical agglomerative clustering method and 1 − correlation as a distance metric. The heat map represents the differentially expressed genes that had fragments per kilobase of transcript per million mapped reads (FPKM) >2 in at least four samples, FDR <0.05 and a log 2 fold change >0.8. Colour represents expression from low (blue) to high (red). GSEAs were performed using GSEA (v.2.2.0, Broad Institute) 36 . The STAT3 target gene list was referred to in a previous report 37 . RNA in situ hybridization by RNAscope or BaseScope. RNA in situ hybridization for examining LIF, LIFR, IL6, IL6R and Ccl11 mRNA cellular localization was performed using RNAscope 2.5 HD Duplex, Multiplex Fluorescent v.2 Assay, or BaseScope Reagent Kit per the manufacturer's instructions (Advanced Cell Diagnostics). In brief, freshly resected tissues were immediately fixed in neutral-buffered formalin for 26 h at room temperature with continuous agitation, processed and embedded in paraffin. Five-micrometre tissue sections were collected in an RNase-free manner and dried at room temperature overnight. Staining was initiated by baking the slides for 60 min at 60 °C, and then slides were deparaffinized. Pretreatment included hydrogen peroxide for 10 min, antigen retrieval for 15 min and protease plus treatment for 15 min at 40 °C. Gene-specific target probe sets designed and supplied by the manufacturer were hybridized for 120 min at 40 °C, and sequential amplification steps were performed, and visualized in red and/or green, or in fluorescence. Immunoblots. Cell lysates were prepared with lysis buffer containing 20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate with freshly added 1 mM Na 3 VO 4 , 1 µg/ml leupeptin and 1 mM PMSF. Protein lysates were resolved on SDS-PAGE gel and immunoblot quantification was carried out on an Odyssey Imager (Licor). α-Tubulin was used as loading control and blotted on the same membranes. The primary antibodies against the following proteins were used with indicated dilution: pSTAT3 (Cell Signaling, 9145, clone D3A7, lot 31; 1:1,000), pAKT1 (Cell Signaling, 4060, clone D9E, lot 23; 1:2,000), and pERK1/2 (Cell Signaling, 4376, clone 20G11, lot 18; 1:1,000), STAT3 (Santa Cruz, sc-8019, lot A1816; 1:500), LIFR (Santa Cruz, sc-659, lot 1714; 1:200), and ACTA2 (Santa Cruz, sc-32251, clone 1A4, lot A1218; 1:5,000), KRT19 (Epitomics, AC-0073, clone EP72, lot EL050102; 1:2,000), α-tubulin (Sigma, clone B-5-1-2, lot 086M4773v, T5186; 1:10,000). ELISA. Frozen tissue specimens were homogenized in cold Tissue Extraction Reagent II (Invitrogen) containing protease and phosphatase inhibitors (Complete mini and PhosSTOP, Roche) at 100 mg tissue per 1 ml and sonicated. Twentyfive microlitres per well tissue lysate or serum without dilution were used for ELISA quantification. Mouse cytokine/chemokine Panel I kit (Millipore, MCYTOMAG-70K), and Human Circulating Cancer Biomarker Panel kit (Millipore, HCCBP1MAG-58K) customized by addition of the anti-LIF antibodies pair using our own anti-LIF monoclonal antibody as capture antibody, were used for mouse and human samples respectively. The manufacturer's standard protocol was followed, and fluorescence intensity acquisition for each well and subsequent concentration calculation were carried out using a Bio-Plex 200 System (Bio-Rad). For the human serum or plasma specimens, Simoa-based ultra-sensitive ELISA assays 38 , also customized with our anti-LIF monoclonal antibody as capture antibody, were performed per Quanterix's optimal protocol. Conditioned media preparation and proteomic secretome profiling. Cells, seeded at high density a day before so as to reach around 95% confluence at use, were washed three times with PBS and then cultured in serum-free medium for 36 h. Conditioned medium was collected and spun down for 5 min at 1,000g and filtered through a 0.22-µm filter. For conditioned-medium stimulation assays on cultured cells, conditioned media were used fresh or stored at 4 °C for no more than three days. For proteomic secretome profiling, the conditioned medium was concentrated by centrifugation through a 3-kDa molecular mass cut-off centrifugal filter (Millipore) at 4,000g for 30 min at 25 °C; PBS was then added and the sample was centrifuged twice more to exchange the buffer. The concentrated proteins were dissolved in 8 M urea buffer containing 20 mM HEPES (pH 8), then reduced with dithiothreitol (Sigma), alkylated with iodoacetamide (Sigma) and digested with sequencing-grade trypsin (Promega). Digested peptides were de-salted using SepPak C18 cartridges (Waters) and fractionated into 28 fractions by using strong-cation exchange (SCX) chromatography (polysulfoethyl aspartamide, 2.1 mm × 200 mm, 5 µm, PolyLC) with 70-min gradient at a flow rate of 0.3 ml/min as reported previously 39 . Peptides in each fraction were then de-salted by homemade C18 StageTip for mass spectrometry analysis. Phosphotyrosine proteomic analysis. MIA PaCa2 or PANC1 cells at around 90% confluence were starved in serum-free medium for 2 h, and then stimulated with freshly prepared conditioned medium or matched serum-free medium as control, for 5 min at 37 °C, washed with ice-cold PBS instantaneously and lysed with 8 M urea buffer containing 20 mM HEPES (pH 8) and 1 mM Na 3 VO 4 . The obtained proteins were reduced, alkylated and digested with TPCK-treated trypsin (Sigma). Digested peptides from two biological replicate samples with stimulation and one control sample were de-salted using SepPak C18 cartridges in parallel and labelled using an on-column three-channel dimethyl labelling protocol 40 . The labelled peptides were then combined at 1:1:1 ratio and phosphotyrosine (pTyr) peptides were immunoenriched by two rounds of immunoprecipitation with 4G10-conjugated agarose beads (Millipore) as described previously 41 . STAT3 IP-MS analysis. IP-MS experiments were performed as described previously 41 . In brief, PANC1 cells stably expressing 3×Flag-tagged STAT3 were serum starved for 2 h, and stimulated with freshly prepared hPSC-conditioned medium for 10 min at 37 °C, then immediately washed with ice-cold PBS and lysed in Nonidet P-40 lysis buffer containing protease and phosphatase inhibitors (Complete mini and PhosSTOP, Roche). The STAT3-associated proteins were immunoprecipitated with anti-Flag M2 beads (Sigma) and subjected to SDS-PAGE separation on NuPAGE 4-12% Bis-Tris Protein Gels (Thermo). To increase the sensitivity to identify membrane receptors usually at higher molecular weight, gel bands above 70 kDa were cut into four slices and subjected to in-gel digestion with sequencing-grade trypsin (Promega). Mass spectrometry analysis and data processing. For secretome profiling, samples were analysed on a TripleTOF 5600 mass spectrometer system (AB SCIEX) as described previously 42 . A 2.5-h total liquid chromatography gradient with 2-35% acetonitrile (ACN) over 120 min was used. The obtained raw files were searched against the IPI human database (v.3.82, 92,104 entries) using Mascot (v.2.3.02) and processed for spectral counting quantification using Scaffold (v.3.4.9). The edgeR 35 package (v.3.6.8) was used for generating the MA plot. Gene Ontology annotation was performed using DAVID (v.6.8). For phosphoproteomic and IP-MS analyses, samples were analysed on an LTQ-Orbitrap Elite mass spectrometer system (Thermo) as described previously 41 . A 3-h total liquid chromatography gradient with 5-35% ACN over 120 min was used. The obtained raw files for phosphoproteomic analysis were processed by MaxQuant (v.1.1.1.36) for dimethyl labelling quantification and database searching against IPI human database (v.3.79, 91,464 entries) with phosphorylation set as variable modification. A minimum ratio count of 2 was required. IP-MS data was processed by MaxQuant (v.1.2.2.5) for label-free quantification with 'match between run' function activated and database searching against the IPI human database (v.3.79). Only proteins quantified in all three biological replicates with peptide >3 and 'Razor + unique peptides' >1 were considered. For global profiling of pancreatic tumour samples (Extended Data Fig. 9b) , the samples were analysed on an Orbitrap Fusion mass spectrometer system (Thermo) as described previously 43 . A 4-h total liquid chromatography gradient with 3-7% ACN for 2 min, 7-22% ACN for 190 min, and 22-35% ACN for 30 min was used. The raw data were searched against the Uniprot human database (70,611 entries, downloaded on 23 July 2016) by using Sequest HT node integrated within the Proteome Discoverer software (v.1.4, Thermo). All the above-mentioned database searching was done with the standard settings expected for the specific annotations. Tissue sample processing with glycoprotein enrichment for PRM-MS assays. Frozen tissue specimens were homogenized in cold lysis buffer containing 100 mM sodium acetate, 150 mM NaCl, 2% SDS, 1% Triton-X 100, pH 5.5 and protease inhibitors (Complete Mini, Roche) and sonicated. Glycosylated proteins, presumably mainly secreted ligands and transmembrane receptors, were selectively enriched using an improved hydrazide chemistry approach 44 . In brief, the glycans in glycoproteins were oxidized by 2 mM sodium periodate (Sigma) for 1 h at 4 °C. Then 2 mM biotin hydrazide (Sigma) was added to react with the aldehyde groups on oxidized glycans. Excess biotin hydrazide and SDS were removed by protein precipitation. The protein pellet was redissolved in 8 M urea buffer containing 100 mM Tris-HCl, pH 7.8, reduced with DTT and alkylated with iodoacetamide as described above. After diluting the urea concentration to 2 M with a solution containing 100 mM Na 2 HPO 4 and 150 mM NaCl, pH 7.5, glycoproteins conjugated with biotin hydrazide were enriched with streptavidin beads (GE Healthcare) and digested with sequencing-grade trypsin (Promega). Peptide samples were fractionated by in-tip high-pH fractionation into five fractions for global profiling or directly de-salted using home-made C18 StageTips for PRM-MS assay. PRM-MS quantification and data analysis. PRM-MS assay was performed on the same Orbitrap Fusion system with the same liquid chromatography setting as global profiling of tumour samples. Thirty-three peptides (5 for LIF, 16 for LIFR and 12 for GP130) identified from various biological samples were programmed for the PRM assay with these criteria applied: unique peptide, no dynamic modification, no more than one missed cleavage, appropriate sequence length and clear mass-fragment spectrum. The PRM acquisition method was developed as described in a previous study 45 by combining a full mass spectrometry scan followed by up to 33 PRM scans of precursor ions within the scheduled retention time window (±25 min of the average retention time detected in the profiling assay). The full mass spectrometry scans were collected from m/z 350 to 1,200 at a resolution of 60,000 (at m/z 200), AGC target of 2 × 10 5 and maximum injection time of 100 ms. Target precursors were then isolated through a window of 2 Th, followed by fragmentation at normalized collision energy of 30%. The product ions were scanned with resolution of 30,000 (at m/z 200), AGC target of 2 × 10 5 and maximum injection time of 120 ms. The PRM raw data were first searched against the Uniprot human database by using Sequest HT. The most frequently identified peptides across all the samples were chosen for quantitation. All raw data were analysed by Skyline (v.3.6.0.10493) 46 to extract and calculate the transition peak areas, and manually inspected by a single experienced person. Data that met the following four criteria: normalized retention time (iRT) within ±2 min, linear regression >0.98, mass difference within ±20 ppm and dot-product (dotp) score ≥0.75, were accepted for further analysis. Relative abundance was calculated by normalizing against the highest intensity in the panel. Animal studies. Mouse tumour wet weight was measured immediately following resection, or tumour volume (Fig. 3f) was calculated using the standard modified ellipsoid formula (1/2) × (length × width 2 ). For all survival studies, the moribund state or maximal tumour size (20 mm in diameter) allowed by our IACUC was used as the clinical endpoint. For caerulein treatment, mice at 7 weeks of age were subjected to 250 mg/kg body weight caerulein ;Pdx1-Cre mice were treated daily for 5 days and rested for 5 days to evaluate tumour initiation; Lifr WT ;Pdx1-Cre or Lifr f/f ;Pdx1-Cre mice were treated daily for 7 days and pancreas tissues were collected 1 or 7 days after the last injection to examine acinar-ductal metaplasia formation and resolution; wild-type CD1 mice (Jax Laboratory, 003814) were treated twice daily for 5 days per week for 2-4 weeks to induce chronic pancreatitis development. For the shortterm treatment for RNA-seq analysis (Fig. 3g, h ), six-week-old KP f/f CL mice were treated with 50 mg/kg Gem twice (on days 1 and 4) plus either 25 mg/kg control IgG or anti-LIF monoclonal antibody three times (on days 1, 3 and 5) in five days, and tumours were resected on day 6. For the maintenance PDAC model (Fig. 4a) , five-week-old KP f/f C mice were administered 50 mg/kg nab-paclitaxel intravenously via the tail vein followed with 80 mg/kg gemcitabine and 4 mg/kg cisplatin intraperitoneally every four days (three times), then after three days off, 50 mg/kg gemcitabine twice weekly together with 25 mg/kg control IgG or anti-LIF monoclonal antibody three times weekly were administered intraperitoneally until the study endpoint. No statistical methods were used to predetermine sample size. For all the animal studies, littermates of the same age were randomly enrolled into the cohorts. Animals were labelled with ID number only, and therefore blinded for genotype during experiments. Flow cytometry, tumour sphere formation and in vivo transplantation assays. Mouse pancreatic tumour dissociation and subsequent flow cytometry analysis or cell sorting for pancreatic tumour sphere formation and in vivo transplantation assays were carried out on a FACSAria III machine and data analysis by FlowJo software (Tree Star) as previously described 28 . Histology and immunostaining. Mouse tumours were resected, fixed in 10% neutral buffered formalin overnight at 4 °C, and paraffin embedded according to standard protocol. Five-micrometre sections were processed for haematoxylin and eosin (H&E), Masson's trichrome or AB-PAS staining per standard protocol. For immunohistochemistry staining, tissue sections were first deparaffinized in xylene and rehydrated in graded ethanols. Antigen retrieval was performed for 15 min in 95-100 °C 10 mM sodium citrate buffer, pH 6.0, or 1 mM EDTA, pH 8.0 (for pSTAT3 antibody). Then, endogenous peroxidase activity was quenched by 3% H 2 O 2 for 10 min. Sections were blocked in TBS containing 0.1% Triton X100 (Sigma) and 5% goat or donkey serum (Vector Laboratories). Incubations with primary antibodies were performed overnight at 4 °C in a humidified chamber, followed with appropriate SignalStain Boost IHC Detection Reagent (Cell Signaling Technology) for 30 min, or with biotinylated secondary antibodies for 45 min and then ABC Elite for 30 min (Vector Laboratories), all at room temperature. ImmPACT DAB Kit (Vector Laboratories) was used to develop signals per manufacturer's instructions. Sections were counterstained with haematoxylin (Sigma). Multiplex immunofluorescence staining was carried out similarly to immunohistochemistry staining, except that sections were blocked in PBS containing 0.1% Triton X100, 10% donkey serum and 5% bovine serum albumin (Millipore), and incubation with Alexa Fluor-conjugated secondary antibodies (Molecular Probes) was performed for 1 h at room temperature. DAPI (Molecular Probes) was used to stain genomic DNA. The following primary antibodies were used with the indicated dilution: mouse anti-ACTA2 (Santa Cruz sc-32251; 1:1,500), rabbit anti-KRT19 (Epitomics AC-0073; 1:200), rabbit anti-phospho-STAT3 (Tyr705) (CST 9145; 1:100), rabbit anti-cleaved caspase-3 (CST 9661, lot 37; 1:200), rabbit anti-Ki67 (Abcam ab15580, lot GR264768-1; 1:3,000), rabbit anti-ZEB1 (Abcam ab87280, lot GR3186880-1; 1:500) and goat anti-PDX1 (Abcam ab47383, lot GR295217-1; 1:5,000). Image acquisition and quantification analysis. Histology and immunohistochemistry images were acquired with a Pannoramic MIDI slide scanner (3DHISTECH). Automated batch quantification of immunohistochemistry images was performed with custom ImageJ 47 macros enabling the Bio-formats plugin 48 . In brief, colour images were converted into 8-bit grayscale images and then a two-threshold strategy was applied to quantify the percentage of positively stained area over total tissue area, denoted as the relative ratio, for each tissue sample. Total tissue area was measured using a low threshold value (threshold = 9, above the background in the blank area), and αSMA + or KRT19 + regions were similarly quantified using appropriately high-threshold values (threshold = 145 and 150, respectively). Fixed threshold values were applied for analysis of all images.
Since both PCCs and PSCs in a certain fraction are proliferating (Ki67 + ) or mesenchymal (ZEB1 + ), to quantitatively assess the ratio of proliferating or mesenchymal cells over the total population of PCCs (PDX1 +   ) 49 specifically, we employed the multiplex immunofluorescence co-staining strategy to mark proliferating or mesenchymal cells and tumour cells independently and simultaneously define the proliferating or mesenchymal tumour cells as those with double-positive signals. Multiplex immunofluorescence tissue section images were acquired using the VS120-L100 Virtual Slide System (Olympus) at 20× objective magnification with a consistent scanning setting across the same set of experiments. Prior to quantification, background subtraction using a 512-µm Gaussian filter was applied. Positivestained nuclear signals were defined by automated surface detection function using Imaris software (Bitplane). Any two surfaces with an overlapping area larger than a fixed threshold (27.56 µm 2 for red and blue, and 78.74 µm 2 for magenta and blue) were counted as double-positive surfaces. The number of blue (DAPI Statistical analysis. Statistical analyses were performed using Prism (v.8.0a, GraphPad Software). Sample sizes were determined on the basis of the variability of pancreatic tumour models used. Tumour-bearing animals were randomly assigned to the treatment groups. Two-tailed unpaired Student's t-test or MannWhitney test (for two-group comparison), one-way ANOVA with Tukey's multiple comparisons test or Kruskal-Wallis test (for multiple-group comparison), and Mantel-Cox log-rank test (for survival comparison) were used where appropriate to determine statistical significance. Tumour tissue LIF levels were correlated to survival time by nonparametric Spearman-correlation test. Coupling the receiver operating characteristic curve (ROC) with its area under the curve (AUC), a widely used method to estimate the diagnostic potential of a classifier in clinical applications, was performed using the pROC package for R 50 . Circulating LIF and CA19-9 concentrations were normalized to the initial time point for each patient to circumvent variations among patients. The disease response codes (0 for partial or good response; 1 for progression, scored by RECIST standard in clinics) were used as the standard to instruct the actual trend of change. For all statistical analyses, *P < 0.05; *P < 0.01; ***P < 0.001, and data are shown as the mean ± s.e.m. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
Data availability
All source data for full immunoblot scan images and statistical analyses presented in figure panels are included in the Supplementary Information. RNA sequencing data have been deposited in the Gene Expression Omnibus under accession numbers GSE99187 and GSE119694. All raw mass spectrometry data have been deposited to the MassIVE repository (ftp://massive.ucsd.edu/MSV000081136).
Code availability
The custom scripts for quantification of immunohistochemistry images with Image J and multiplex immunofluorescence images with Imaris will be freely available upon reasonable request.
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searching against the IPI human database (v3.79). For global profiling of pancreatic tumour samples, raw data were searched against the Uniprot human database (70611 entries, downloaded on July 23, 2016) using Sequest HT node integrated within the Proteome Discoverer software (v1.4, Thermo). The PRM raw data were searched against the Uniprot human database by Sequest HT, and then quantified by Skyline (v3.6.0.10493). Flow cytometry data were analyzed with FlowJo software (Tree Star). Statistical analysis were done by Prism 8.0, except ROC curve by pROC package for R.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability
In the Methods part, we enclosed a "Data availability" section, stating that "RNA sequencing data have been deposited in the Gene Expression Omnibus under accession numbers GSE99187 and GSE119694. All MS raw data have been deposited to the MassIVE repository (ftp://MSV000081136@massive.ucsd.edu). The custom scripts for quantification of IHC images with Image J and multiplex immunofluorescence images with Imaris will be freely available upon request."
Field-specific reporting Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size
This was a study where the "effect magnitude" was unknown and therefore power was not calculated. Approximated sample sizes (n>10 for in vivo animal study) were estimated based on the general experiences and the variability of pancreatic tumour models used. p values were statistically calculated to determine the significance where applicable.
Data exclusions All animals and samples generated for the purpose of these studies were included, except the obvious outliers identified by Prism ROUT analysis (Q<0.5), the standard criteria commonly used.
Replication
For all the findings reported in the paper, at least three independent experiments were performed, and all the data were included for analysis and presented, except for qualitative experiments, e.g. immunoblot, the representative results were presented and stated in corresponding figure legends. All experiments were successfully replicated with the properly optimized condition.
Randomization For all the preclinical studies, including Gem vs saline treatment on KPf/fCL;LIFRf/f mice (Fig. 2) , and cerulein-treated KC;LIFRf/f mice (Extended Data Fig. 3h,i) , four-arm preclinical trials using KPf/fCL mice (Fig. 3 ), maintenance KPC model with triple chemotherapy pretreatment (Fig. 4) , littermates at the same age were randomly enrolled into the cohorts. In all cases, when the treatment started, the mice were all grossly/visually healthy and body weight was not significant different, so randomly assigned into the cohorts of treatments.
Blinding
All the enrolled mice or subsequent samples were labelled only with mouse ID numbers and did not indicate genotype or type of treatment. Genotype or treatment type were decoded after the data acquisition and quantification analysis were complete.
Reporting for specific materials, systems and methods 
Mycoplasma contamination
For the established human cell lines received from ATCC and other resources and routinely cultured in the lab, mycoplasma contamination was tested by the MycoAlertTM PLUS Mycoplasma Detection Kit (Lonza), and all are negative. For the primary lines, 10 mg/L ciprofloxacin was added in the culture media to prevent the mycoplasma contamination.
Commonly misidentified lines (See ICLAC register)
None.
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research
Laboratory animals
KrasLSL-G12D/+;Trp53flox; Rosa26LSL-Luc compound mutant mice (designated as KPf/fL mice) on FVB background were kindly provided by R. Shaw (Salk). Pdx1-Cre mice (stock # 014647) were purchased from The Jackson Laboratory, and backcrossed with KPf/fL mice for at least 6 generations before phenotypic analysis. Frozen sperm of C57BL/6N-Lifrtm1a(EUCOMM)Hmgu/H were purchased from the European Mouse Mutant Archive (EMMA) (order ID: 06941) and rederived by in vitro fertilization in the Salk Transgenic Core Facility to obtain the mutant mice (tm1a) harboring a knockout first allele (reporter-tagged insertion with conditional potential), and then crossed with FLPo mice, Gt(ROSA)26Sortm2(FLP*)Sor/J, to delete the FRT-LacZ-Neo-FRT selection cassette and convert into Lifrflox (tm1c) strain with conditional allele. No phenotypic differences were noticed between Lifr+/+ and Lifrf/+ mice, and therefore data from Lifr+/+ and Lifrf/+ mice were combined and designated as LifrWT mice. No sexual dimorphism was noted in any mouse model, and therefore males and females were equally used for experimental purposes and both sexes are represented in all data sets. Age of mice used for experiments were annotated corresponding in Figure Legends and Methods part.
Wild animals
Field-collected samples
